Lapatinib, used in the form of lapatinib ditosylate, is marketed by GSK as Tykerb or Tyverb. Lapatinib ditosylate is classified as S/NM (a synthetic compound showing competitive inhibition of the natural product) that is naturally derived or inspired substrate. This product is approved in at least one country to treat patients with advanced metastatic breast cancer.
Cancer Research and Antivirals
Send us your enquiry for Lapatinib Ditosylate. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Lapatinib Ditosylate email us and we will include your contribution on the website.